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Supplementary Figure 1. The specificity of an Ipom-F induced translocational 
block is consistent and reproducible in ER-derived microsomes and SP cells, 
Related to Figures 1-6. 
The tail-anchored protein precursors, (Ai) C-terminally OPG2-tagged cytochrome b5 
(Cytb5OPG2) and (Aii) C-terminally OPG2-tagged Sec61 beta subunit 
(Sec61βOPG2); secretory proteins, (Bi) bovine preprolactin (PPL) and (Bii) yeast 
prepro-alpha-factor (ppαF); single-pass type I transmembrane protein (TMP), (C) T-
cell surface glycoprotein CD3 delta chain (CD3δ) and single-pass type II TMP (D) 
asialoglycoprotein receptor 1 (ASGR1) were synthesised in rabbit reticulocyte lysate 
supplemented with ER-derived canine pancreatic microsomes in the presence and 
Page 3 of 32 
 
absence of 1 µM Ipom-F. (E) The effect of 1 µM Ipom-F on insertion into both ER-
derived microsomes and SP cells was determined using a model substrate from 
each class of single-pass TMP; the type I TMP, vascular cell adhesion protein 1 
(VCAM1), the type II TMP, isoform 2 (residues 17-232) of the short form of HLA 
class II histocompatibility antigen gamma chain (Ii) and the type III TMP OPG2Vpu 
(as Fig. 1di). Phosphorimages of membrane-associated products resolved by SDS-
PAGE together with representative substrate outlines are shown. N-glycosylation or 
signal sequence cleavage were used as a read-out for the qualitative efficiency of 
translocation/insertion. N-glycosylated (X-Gly) versus non-N-glycosylated (0Gly) 
species were identified by treatment with endoglycosidase H (Endo H, lane 2). Sc, 
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Human Dog Sequence 
identity 
EMC1 Core subunit Type I TMP 112 Q8N766 F1PN78 95.5% 
EMC2 Core subunit Cytosolic 35 Q15006 E2R0P8 100% 
EMC3 Core subunit Multi-pass 
TMP 
30 QP012 E3RMQ3 99.5% 
EMC4 X Multi-pass 
TMP 
20 Q5J8M3 E2R5T1 97.8% 
EMC5 Core subunit Multi-pass 
TMP 
15 Q8N4V1 N/A N/A 
EMC6 Core subunit Multi-pass 
TMP 
12 Q8N766 E2R7Q9 99.1% 
EMC7 X Type I TMP 26 Q9NPA0 J6P692 95.5% 
EMC8 X Cytosolic 24 O4302 E2QUA5 98.6% 
EMC9 X Cytosolic 23 Q9Y3B6 F6UPE2 92.7% 
EMC10 X Type I TMP 27 Q5UCC4 E2R112 92.0% 
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Supplementary Figure 2. The human EMC is a 9-subunit multimeric complex, 
Related to Fig. 2.  
(A) A schematic of the structure of the human EMC, depicting its tripartite 
organisation across the ER membrane (a basket-shaped cytosolic region, an 
ordered membrane-spanning core and an L-shaped ER lumenal region)1,2,3 and the 
topology of each of its subunits; three soluble/cytosolic (EMC2, EMC8, EMC9), three 
single-pass type I TMPs (EMC1, EMC7, EMC10), three multi-pass TMPs (EMC3, 
EMC5, EMC6) and one topologically ambiguous subunit whose N-terminus is 
cytosolic3,4 but may be comprised of one1,2,3, two5 or three2,3 transmembrane 
domains (EMC4). Of these 10 subunits, EMC8 and EMC9 are functional paralogues, 
thus the EMC complex may either be comprised of EMC1-8 or EMC1-7,9 together 
with EMC101,2,3. In addition, EMC6 is topologically dependent on the presence of 
EMC5, whereby the poorly hydrophobic first transmembrane domain of EMC6 is only 
capable of inserting into the membrane upon assembly with EMC51. EMC subunits 
with variable or an unconfirmed number of TMDs are indicated by (*). (B) Based on 
subunit depletion studies, and consistent with its ER membrane organisation, EMC1, 
EMC2, EMC3, EMC5, EMC6 are structurally integral to the assembly of the wider 
EMC complex1,6. Subunits EMC1-10, whether structurally integral or not, are highly 
conserved between humans and dogs, with the exception of EMC5 which is not 
present at all in dogs. (C) The structurally-integral subunit human EMC5 (H. sapiens, 
Q8N4V1-1) is conserved in yeast (S. cerevisiae, P40540, 22% identity, 54% 
similarity) and shares high homology with its sheep (O. aries, W5PPL4, 79% identity, 
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Supplementary Figure 3. The OPG2-tag does not affect Ipom-F sensitivity of 
TMPs and permits efficient recovery of TMP substrates by 
immunoprecipitation independent of OPG2-tag location, Related to Figures 1-2 
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and 4-6. (A) An N-terminal fragment of bovine rhodopsin containing two sites for N-
glycosylation (OPG2-tag) was incorporated either at the N-terminus (residues 1-26 
rhodopsin) or C-terminus (residues 2-18 rhodopsin) of model TMPs. (B) 
Phosphorimages of the membrane-associated radiolabelled products synthesised in 
ER-derived canine pancreatic microsomes. Precursor polypeptides include OPG2-
tagged (Bi) asialoglycoprotein receptor 1 (ASGR1OPG2), (Bii) small cell adhesion 
glycoprotein containing an artificial N-glycan site (SMAGPOPG2), (Biii) glycophorin 
C (GypCOPG2), (Biv) tumour necrosis factor receptor superfamily member 17 
containing an artificial N-glycan site (BCMAOPG2), (Bv) synaptotagmin 1 
(Syt1OPG2), (Bvi) a truncated version of Syt1OPG2 (Syt1-127-OPG2) and (Bvii) a 
non-tagged version of Syt-127-OPG2 (Syt1-127). (C) Each of the OPG2-tagged 
precursor polypeptides used in this study were synthesised with semi-permeabilised 
cells, recovered via the OPG2-tag by immunoprecipitation (IP1; lanes 1 and 2) and 
analysed by SDS-PAGE and phosphorimaging. Any remaining proteins contained in 
the supernatant were then isolated by immunoprecipitating a second time (IP2; lanes 
3 and 4). Inputs are 10% of the total material. The relative efficiencies of TMP 
recovery were calculated as a ratio of the total signal intensity present in IP1 
compared to that in present in IP1+IP2. Quantifications are given as means ±SEM 
for three independent immunoprecipitations (n=3). (!) indicates a slightly reduced 
calculation of recovery due to the presence of radiolabelled material unrelated to the 
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Supplementary Figure 4. Predicted hydrophobicity of transmembrane domains 
from human type III TMPs, Related to Figures 1-7. 
Predicted transmembrane domain (TMD) hydrophobicity values (∆Gapp)5, the number 
of charged and/or polar amino acid residues in the transmembrane domain and 
lumenal/cytoplasmic (Nexo/Ccyt) domain lengths were calculated by inputting the 
protein sequences of 38 human, 1 rat (Syt1) and 1 viral (HIV-Vpu) type III TMPs 
(Uniprot annotated) into the ‘full protein scan’ mode using http://dgpred.cbr.su.se/. 
Type III TMPs analysed in this study are in yellow. All other Uniprot annotated type 
III TMPs that enter the secretory pathway (i.e. are localized in the ER, Golgi 
apparatus or plasma membrane) are in black. For a full list of type III TMPs 
analysed, and those discounted from analysis, see Supplementary Data 1. Charged 
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Supplementary Figure 5. Knockdowns of subunits of the Sec61, EMC and/or 
SRP receptor complexes variably affect the levels of ER protein translocation 
components, Related to Figures 2-6. 
(Ai) Representative structures of known membrane-bound receptors involved in 
protein translocation. The SRP-(signal recognition particle) receptor (co-translational 
pathway) is a heterodimer comprised of the membrane-integrated beta-subunit 
(SRβ) which anchors the peripherally associated cytosolic alpha-subunit (SRα) to the 
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ER membrane. SRα binds to SRP and transfers SRP-targeted ribosome nascent 
chains to the Sec61 complex7. hSnd2 (co/post-translational pathway) is the human 
orthologue of a component involved in the distinct SRP-independent (SND) targeting 
pathway present in yeast8. hSnd2 plays a role in the ER targeting of certain proteins, 
although this pathway is yet to be fully defined in humans9. Here, we show hSnd2 as 
a TMP containing three transmembrane domains5,10, although a four transmembrane 
domain model has also been hypothesised9. The TRC40 receptor (post-translational 
pathway), comprised of the WRB and CAML-(calcium signal-modulating cyclophilin 
ligand) membrane proteins, may either insert TRC40-targeted tail-anchor proteins 
into the ER membrane directly11 or re-route certain proteins to the Sec61 complex12. 
(Aii) A schematic of SRP-(signal recognition particle) which is comprised of a highly 
base paired SRP RNA (7SL) and six protein subunits (SRP9, SRP14, SRP19, 
SRP54, SRP68 and SRP72) that are assembled into a functionally independent Alu 
domain (responsible for translational retardation) and the S domain (signal sequence 
engagement and SRP receptor binding). Each subunit of the S domain is essential 
for SRP function whereas those of the Alu domain are dispensable for protein 
translocation/insertion7. (B) The effect on SRα, hSnd2, CAML and SRP54 of 
transfecting HeLa cells with non-targeting (NT; lanes 1, 5, 8 and 10), Sec61α-
targeting (lane 2), EMC2-targeting (lane 3), EMC5-targeting (lane 4), 
Sec61α+EMC2-targeting (lane 6), Sec61α+EMC5-targeting (lane 7), SRα-targeting 
(lane 9), SRα+EMC5-targeting (lane 11) and SRα+Sec61α-targeting (lane 12) 
siRNAs were determined after semi-permeabilisation by immunoblotting. (C) The 
effects of each siRNA-mediated knockdown were calculated as a proportion of the 
signal intensity obtained with the NT control (set as 100%). Quantifications are given 
as means ±SEM for two or three separate siRNA treatments (n=2 or n=3 as 
indicated in figure) with statistical significance of siRNA-mediated knockdowns (two-
way ANOVA) determined using Sidak’s multiple comparisons test. Statistical 
significance is given as n.s., non-significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
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Supplementary Fig. 5b: NT, Sec61α-kd, EMC2-kd, EMC5-kd, Sec61α+EMC2-kd, Sec61α+EMC5-kd, SRα-kd, SRα+EMC5-kd, 
SRα+Sec61α-kd Western blots 
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Page 12 of 32 
 
 


















Page 13 of 32 
 




































































































Page 16 of 32 
 



































Page 17 of 32 
 








































































Page 19 of 32 
 




















Page 20 of 32 
 



































Page 21 of 32 
 



































Page 22 of 32 
 








































































Page 24 of 32 
 



































Page 25 of 32 
 



































Page 26 of 32 
 
Supplementary Fig. 5b: NT, Sec61α-kd, EMC2-kd, EMC5-kd, Sec61α+EMC2-kd, Sec61α+EMC5-kd, SRα-kd, SRα+EMC5-kd, 
SRα+Sec61α-kd Western blots 
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Knockdowns of Sec61α, EMC2, EMC5, Sec61α+EMC5  (lanes 1-4, 7, right panels) 
